Mohammadi 2010.

Methods	A 6‐week, parallel group, double‐blind, randomised clinical trial with 2 arms: Methylphenidate Amantadine
Participants	Number of participants screened: 65 Number of participants included: 40 Number of participants randomised to methylphenidate: 20 Number of participants followed up: 19 Number of withdrawals: 1. Diagnosis of ADHD: DSM‐IV (subtype: combined (100%)) Age: mean 9.25, range 6‐14 years old IQ: > 70 Sex: 13 males, 7 females Methylphenidate‐naïve: 100% Ethnicity: not stated Country: Iran Comorbidity: none Comedication: none Sociodemographics: not stated Inclusion criteria 6‐14 years old DSM‐IV‐TR diagnosis of ADHD Total or subscale scores (or both) on ADHD‐RS‐IV School Version of ≥ 1.5 SD above norms for patient's age and gender Parents and children had to be willing to comply with all requirements of the study Exclusion criteria A history or current diagnosis of pervasive developmental disorders, schizophrenia or other psychiatric disorders (DSM‐IV axis I) Any current psychiatric comorbidity that required pharmacotherapy Any evidence of suicide risk and mental retardation (IQ < 70) A clinically significant chronic medical condition, including organic brain disorder, seizures and, current abuse or dependence on drugs the last 6 months, hypertension or hypotension
Interventions	Methylphenidate type: Ritalin Methylphenidate dosage: 20‐30 mg/day depending on weight (20 mg/day for < 30 kg and 30 mg/day for > 30 kg) Mean methylphenidate dosage. At week 6: 25.50 mg (SD 5.10) Titration period: 3 weeks after randomisation Duration of intervention: 6 weeks Treatment compliance: not stated
Outcomes	Side effects checklist that comprises 20 side effects including psychic, neurologic, autonomic and other side effects, administered by a child psychiatrist on days 7, 21 and 42 Body weight and vital signs were measured at baseline and weeks 1, 2, 4 and 6 12‐lead ECG and physical examinations were evaluated at baseline and week 6 Haematology tests were collected at baseline and weeks 2, 4 and 6; serum chemistry and urinalysis were evaluated at baseline and week 6
Notes	Sample calculation: not stated Ethics approval: yes Funding: the study was supported by a grant from Tehran University of Medical Sciences. Vested interests/authors' affiliations: not stated Key conclusions of the study authors: the results of this study indicate that amantadine significantly improved symptoms of ADHD and was well tolerated and it may be beneficial in the treatment of children with ADHD. Nevertheless, the present results do not constitute proof of efficacy Supplemental information requested from the study authors twice in July and August 2013 with no reply